Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan

Table 2 IFX concentration by age group

	6 to < 12 years		12 to 17 years
	μg/mL, median (IQR)	n	μg/mL, median (IQR)	n
1 h after administration at Week 0	92.87 (76.62, 107.71)	4	97.17 (91.53, 107.43)	17
Week 8	20.65 (12.00, 23.08)	3	28.34 (20.39, 35.03)	16
Week 14	0.85 (0.26, 3.45)	3^a	3.11 (0.80, 6.06)	15^a
Week 22	0.34 (0.33, 0.57)	3^a	2.65 (0.48, 5.21)	12^a
Week 30	1.20 (0.00, 1.48)	3^a	2.62 (0.00, 5.78)	11^a

ISSN: 1471-2431